close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

44.48 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,022
Open 44.48
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 44.48
Today's Range 44.48 - 44.48
52wk Range 34.10 - 45.94
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Approves Alzheimer’s Test Developed By Roche In Collaboration With Eli Lilly
The blood-based test is aimed at aiding the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting in patients aged 55 and older. 
Via Stocktwits
Genentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Types
From Genentech
Via Business Wire

Performance

YTD
+27.3%
+27.3%
1 Month
+8.5%
+8.5%
3 Month
+10.6%
+10.6%
6 Month
+15.3%
+15.3%
1 Year
+13.0%
+13.0%

More News

Read More
Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $4.7 Billion Buyout
Via Investor's Business Daily
Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market
Via The Motley Fool
89bio Stock Skyrockets After Roche’s $3.5B Buyout Offer: Retail Bullish, But A Wall Street Analyst Is Cautious
Via Stocktwits
Why Did 89bio Stock Nearly Double In Value Today?
Via Stocktwits
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)
From Brodsky & Smith LLC
Via GlobeNewswire
FDA Greenlights Jazz and Roche's Zepzelca-Tecentriq for ES-SCLC Maintenance, Reshaping Lung Cancer Treatment Landscape
Via MarketMinute
FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
From Genentech
Via Business Wire
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
Via TokenRing AI
Topics Artificial Intelligence
GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley
Via Investor's Business Daily
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Via Benzinga
Topics Government World Trade
Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now
Via The Motley Fool
Topics Artificial Intelligence
Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America
Via Stocktwits
Topics Government
Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch
Via Benzinga
Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025
From Genentech
Via Business Wire
Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’
Via Stocktwits
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
Via MarketMinute
Topics Economy Intellectual Property
Roche Targets Top Spot In Weight Loss Drug Market
Via Benzinga
Positive Phase III Results Show Genentech’s Giredestrant Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer
From Genentech
Via Business Wire
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
The Healthcare Horizon: Navigating Innovation, Policy Shifts, and Evolving Patient Care
Via MarketMinute
Topics Artificial Intelligence
Deal Dispatch: Need M&A Approval? FCC Chair Explains How To Get It
Via Benzinga
Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push
Via Benzinga
Roche Digs Into Obesity-Tied Diseases With $3.5 Billion 89bio Buyout
Via Investor's Business Daily

Frequently Asked Questions

Is Roche Holding AG Basel American Depositary Shares publicly traded?
Yes, Roche Holding AG Basel American Depositary Shares is publicly traded.
What exchange does Roche Holding AG Basel American Depositary Shares trade on?
Roche Holding AG Basel American Depositary Shares trades on the OTC Traded
What is the ticker symbol for Roche Holding AG Basel American Depositary Shares?
The ticker symbol for Roche Holding AG Basel American Depositary Shares is RHHBY on the OTC Traded
What is the current price of Roche Holding AG Basel American Depositary Shares?
The current price of Roche Holding AG Basel American Depositary Shares is 44.48
When was Roche Holding AG Basel American Depositary Shares last traded?
The last trade of Roche Holding AG Basel American Depositary Shares was at 10/15/25 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today